Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma

European Journal of Radiology

Volumn 81, Issue 5, 2012, Pages 1024-1028

  Shum, Weng Yoon ^a,c   Hsieh, Te Chun ^a,e   Yeh, Jun Jun ^b,d   Chen, Jin Hua ^a   Su, Chih Chung ^c   Liang, Ji An ^b,e   Kao, Chia Hung ^b,e  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c JEN AI HOSPITAL   (Taiwan)

^d PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

2 18F fluoro 2 deoxy d glucose (FDG); Esophageal squamous cell carcinoma; Positron emission tomography computed tomography (PET CT); Retention index (RI); Standardized uptake value (SUV max)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACCURACY; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MALE; PATHOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80051904977     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2011.03.018     Document Type: Article

References (33)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52. (Pubitemid 37485141)
2. Okada M, Murakami T, Kumano S, et al. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer. Ann Nucl Med 2009;23:73-80.
3. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005;129:1232-41. (Pubitemid 40804839)
4. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-60, discussion 60.
5. Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002;94:921-8. (Pubitemid 34150845)
6. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496-507. (Pubitemid 43200300)
7. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004;22:3805-12. (Pubitemid 41095222)
8. Erasmus JJ, Munden RF. The role of integrated computed tomography positronemission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol 2007;17:29-37. (Pubitemid 44918359)
9. Kato H, Kimura H, Nakajima M, et al. The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer. Oncol Rep 2008;20:857-62.
10. Yuan S, Yu Y, Chao KS, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 2006;47:1255-9. (Pubitemid 47544876)
11. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301-6.
12. Demura Y, Tsuchida T, Ishizaki T, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003;44:540-8. (Pubitemid 39663420)
13. Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 2009.
14. Straver ME, Aukema TS, Olmos RA, et al. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging 2010;37:1069-76.
15. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 2005;46:1819-24. (Pubitemid 46196643)
16. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308-12. (Pubitemid 24243143)
17. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22-30. (Pubitemid 29137735)
18. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-5. (Pubitemid 34747808)
19. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001;28:696-703.
20. Tian R, Su M, Tian Y, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol 2009;38:451-8.
21. Laffon E, de Clermont H, Begueret H, et al. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun 2009;30:455-61.
22. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-7. (Pubitemid 32852620)
23. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole body imaging. Semin Nucl Med 1998;28:352-8. (Pubitemid 28478048)
24. Hu Q, Wang W, Zhong X, et al. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer. Eur J Radiol 2009;70:320-4.
25. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-84. (Pubitemid 28108743)
26. Hellwig D, Graeter TP, Ukena D, et al. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med 2007;48:1761-6. (Pubitemid 350099319)
27. Hsu WH, Hsu PK, Wang SJ, et al. Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg 2009;87:1564-8.
28. Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2006;82:391-4, discussion 4-5.
29. Choi JY, Jang HJ, Shim YM, et al. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 2004;45:1843-50.
30. Choi JY, Lee KH, Shim YM, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000;41:808-15. (Pubitemid 30266024)
31. Hofstetter W, Correa AM, Bekele N, et al. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg 2007;84:365-73, discussion 74-5.
32. Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002;137:1001-6, discussion 6-7.
33. Liberale G, Van Laethem JL, Gay F, et al. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol 2004;30:942-7. (Pubitemid 39462523)